Default Category
-
Paydiant
Alvarez, Jose B.; Williamson, Elizabeth C.; Weber, JamesCase HBS-511065-EMarketingTo maximize their effectiveness, color cases should be printed in color. Kevin Laracey, founder of Paydiant, needed to figure out how to launch a payment processing company with a new technology based on smart phones. Consumers had increasingly turned to electronic payment methods such as credit cards and debit cards to make purchases. Retailers, however, felt that major credit and debit card issuers had too much market power which was leading to...Starting at €8.20
-
Pfizer and AstraZeneca: Marketing an Acquisition (B)
Quelch, John A.; Weber, JamesCase HBS-515008-EMarketingThis (B) case provides a brief description of the outcome of the (A) case.Starting at €5.74
-
Orb: The Next Big Thing (A)
Pedro M Gardete, Debra SchifrinCase SGSB-M363A-EMarketingIn 2003, the tiny start-up Orb came up with a breakthrough technology. Through its software, every type of media on a PC (including music, photos, and videos) could be streamed remotely to any mobile device for free. Orb also enabled users to stream live TV onto their PCs and mobile devices. This was a technological feat in the days before the iPhone and other smartphones. When Orb launched in 2005, it won the “Next Big Thing” award from the inf...Starting at €8.20
-
Orb: The Next Big Thing (A) - Teaching Note
Pedro M Gardete, Debra SchifrinTeaching Note SGSB-M363TN-EMarketingIn 2003, the tiny start-up Orb came up with a breakthrough technology. Through its software, every type of media on a PC (including music, photos, and videos) could be streamed remotely to any mobile device for free. Orb also enabled users to stream live TV onto their PCs and mobile devices. This was a technological feat in the days before the iPhone and other smartphones. When Orb launched in 2005, it won the “Next Big Thing” award from the inf...Starting at €0.00
-
Pfizer and AstraZeneca: Marketing an Acquisition (A)
Quelch, John A.; Weber, JamesCase HBS-515007-EMarketingIn 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to the challenges of developing new drugs. Over the previous decade or more, Pfizer had pursued acquisitions as a way to acquire new drugs, increase sales, and to reduce costs by comb...Starting at €8.20